ExploreWatchlistsPricing
  1. JP-listed companies
  2. Immuno-Biological Laboratories Co., Ltd.
  3. Financials
  4. Stockholders' equity

Immuno-Biological Laboratories Co., Ltd. (4570)

Market cap
¥14.1B
P/E ratio
53.1x
Develops antibody-based diagnostic tools and testing services for medical research, plus manufactures cosmetics using human-type collagen from silkworms.
SummaryFinancialsDividendsHistorySegmentsOwnershipWorkforce
Period EndStockholders' equity (Million JPY)YoY (%)
Mar 31, 20251,514+19.68%
Mar 31, 20241,265+17.31%
Mar 31, 20231,079-21.17%
Mar 31, 20221,368-16.02%
Mar 31, 20211,629-16.38%
Mar 31, 20201,948-9.20%
Mar 31, 20192,146+6.34%
Mar 31, 20182,018+50.42%
Mar 31, 20171,341-51.86%
Mar 31, 20162,786+6.37%
Mar 31, 20152,620-6.27%
Mar 31, 20142,795

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat